10-KPeriod: FY2009

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2009

Filed February 19, 2010For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) reported its annual results for the fiscal year ended December 31, 2009. The company is heavily invested in the development of telaprevir, a potential treatment for Hepatitis C (HCV), with an anticipated New Drug Application (NDA) submission in the second half of 2010 and a potential US launch in 2011. Significant research and development efforts are also underway for VX-770, a drug candidate for cystic fibrosis (CF). The company experienced a substantial increase in net loss for 2009 compared to 2008, primarily due to lower revenues and increased operating expenses associated with expanded workforce and late-stage clinical programs. Financially, Vertex ended 2009 with a strong cash position of $1.3 billion, bolstered by equity and debt offerings, as well as milestone payments from collaborations. However, the company continues to incur significant operating losses, and future profitability is contingent upon the successful commercialization of its drug pipeline, particularly telaprevir. Investors should closely monitor the progress of telaprevir's clinical trials and regulatory submissions, as well as the company's ongoing investments in research and development.

Financial Highlights

44 data points
Beta

Revenue

$101.89M

Net Income

-$642.18M

-630.3% Net Margin

EPS (Diluted)

$-3.71

Total Assets

$1.96B

Cash & Equivalents

$446.66M

Free Cash Flow

-$451.08M

Financial Statements
Beta
Revenue$101.89M
R&D Expenses$550.27M
SG&A Expenses$130.19M
Operating Expenses$715.90M
Operating Income-$614.01M
Interest Expense$13.19M
Net Income-$642.18M
EPS (Basic)$-3.71
EPS (Diluted)$-3.71
Shares Outstanding (Basic)173.26M
Shares Outstanding (Diluted)173.26M

Key Highlights

  • 1Vertex Pharmaceuticals is advancing telaprevir, an oral protease inhibitor for Hepatitis C, with plans to submit an NDA in the latter half of 2010 and launch in the US in 2011.
  • 2The company is also developing VX-770, a drug candidate for cystic fibrosis, with a registration program underway.
  • 3Net loss increased significantly in 2009 to $642.2 million from $459.9 million in 2008, driven by lower revenues and higher operating expenses.
  • 4Vertex ended 2009 with a robust cash balance of $1.3 billion, providing funding for ongoing development activities.
  • 5Significant investments are being made in research and development, with R&D expenses totaling $550.3 million in 2009.
  • 6The company's strategy involves expanding its commercial organization in preparation for the potential launch of telaprevir.
  • 7Collaborations with companies like Janssen and Mitsubishi Tanabe are crucial for the development and commercialization of telaprevir.

Frequently Asked Questions

Vertex Pharmaceuticals' lead drug candidate is telaprevir, an oral protease inhibitor for the treatment of Hepatitis C (HCV). It is currently in a registration program, with plans to submit a New Drug Application (NDA) to the FDA in the second half of 2010 and a potential US launch in 2011.

In 2009, Vertex Pharmaceuticals reported a net loss of $642.2 million, an increase from $459.9 million in 2008. This was primarily due to lower revenues, stemming from a decrease in milestone payments, and increased operating expenses, particularly in research and development and sales, general, and administrative functions, as the company expanded its workforce and advanced its late-stage clinical programs.

Future profitability for Vertex Pharmaceuticals is heavily dependent on the successful development and commercialization of its drug pipeline, most notably telaprevir for Hepatitis C. The company continues to invest heavily in research and development, and it is expected to incur significant operating losses until substantial product revenues are generated, which is anticipated to begin in 2011 with the potential launch of telaprevir.

Vertex Pharmaceuticals' key strategic priorities include obtaining FDA approval and effectively commercializing telaprevir, building a fully-capable biopharmaceutical company by establishing a strong sales and marketing organization, investing in research and early/mid-stage development programs, and capitalizing on collaboration arrangements and business development opportunities.